Xeris Biopharma Holdings
XERS
103 hedge funds and large institutions have $150M invested in Xeris Biopharma Holdings in 2021 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 39 increasing their positions, 25 reducing their positions, and 12 closing their positions.
665% more call options, than puts
Call options by funds: $10.3M | Put options by funds: $1.35M
58% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 12
56% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 25
19% more capital invested
Capital invested by funds: $126M → $150M (+$23.4M)
7% more funds holding
Funds holding: 96 → 103 (+7)
2.32% less ownership
Funds ownership: 52.37% → 50.05% (-2.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$35.3M |
| 2 |
Renaissance Technologies
New York
|
+$5.15M |
| 3 |
TA
Tamarack Advisers
Carlsbad,
California
|
+$1.89M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.8M |
| 5 |
Morgan Stanley
New York
|
+$1.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Sessa Capital
New York
|
-$4.07M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$3.7M |
| 3 |
6CM
683 Capital Management
New York
|
-$877K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$783K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$733K |
XERS Hedge Fund Activity: Q1 2021 in Review
103 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q1 2021, worth a combined $150M — up 19% from $126M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new XERS positions and 12 closed out — a net gain of 7 holders — while 39 added to existing stakes and 25 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $35.3M. The largest seller was Sessa Capital, cutting an estimated $4.07M.
- 103 institutional investors held Xeris Biopharma Holdings (XERS) as of Q1 2021, up from 96 in Q4 2020.
- Funds reported $150M of Xeris Biopharma Holdings stock for Q1 2021, up 19% quarter-over-quarter.
- 19 funds opened new Xeris Biopharma Holdings positions in Q1 2021 and 12 closed out, a net change of +7 holders.
- The largest Xeris Biopharma Holdings buyer in Q1 2021 was Deerfield Management, an estimated $35.3M added.
- The largest Xeris Biopharma Holdings seller in Q1 2021 was Sessa Capital, an estimated $4.07M sold.
Based on aggregated 13F filings for Q1 2021.